Related Experiment Video
Updated: Mar 17, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible
Geoffrey D Clapp1, Thomas Lepoutre2, Franck E Nicolini3
1Department of Mathematics and Center for Scientific Computation and Mathematical Modeling (CSCAMM), University of Maryland , College Park, MD, USA.
Abstract:
Many chronic myelogenous leukemia (CML) patients in chronic phase who respond well to imatinib therapy show fluctuations in their leukemic loads in the long-term. We developed a mathematical model of CML that incorporates the intervention of an autologous immune response. Our results suggest that the patient's immune system plays a crucial role in imatinib therapy in maintaining disease control over time. The observed BCR-ABL/ABL oscillations in such patients provide a signature of the autologous immune response.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

